72.23
price up icon1.43%   1.02
after-market アフターアワーズ: 72.00 -0.23 -0.32%
loading
前日終値:
$71.21
開ける:
$71.49
24時間の取引高:
1.65M
Relative Volume:
1.12
時価総額:
$13.78B
収益:
$2.75B
当期純損益:
$322.29M
株価収益率:
43.25
EPS:
1.67
ネットキャッシュフロー:
$300.88M
1週間 パフォーマンス:
+1.50%
1か月 パフォーマンス:
+12.98%
6か月 パフォーマンス:
-14.09%
1年 パフォーマンス:
-15.90%
1日の値動き範囲:
Value
$71.16
$73.51
1週間の範囲:
Value
$69.89
$73.51
52週間の値動き範囲:
Value
$60.63
$94.85

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
名前
Biomarin Pharmaceutical Inc
Name
セクター
Healthcare (1184)
Name
電話
(415) 506-6700
Name
住所
105 DIGITAL DRIVE, NOVATO, CA
Name
職員
3,401
Name
Twitter
Name
次回の収益日
2024-10-29
Name
最新のSEC提出書
Name
BMRN's Discussions on Twitter

BMRN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
72.23 13.78B 2.75B 322.29M 300.88M 1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
488.29 125.39B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
707.51 77.35B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
594.21 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
244.52 31.65B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.07 26.47B 3.32B -860.46M -1.04B -8.32

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-24 アップグレード Oppenheimer Perform → Outperform
2024-11-15 開始されました Wolfe Research Outperform
2024-10-30 ダウングレード William Blair Outperform → Mkt Perform
2024-10-10 再開されました Raymond James Outperform
2024-08-20 アップグレード Bernstein Mkt Perform → Outperform
2024-05-17 ダウングレード Robert W. Baird Outperform → Neutral
2024-05-14 開始されました Evercore ISI Outperform
2023-11-15 開始されました Wells Fargo Overweight
2023-10-23 アップグレード Bernstein Underperform → Mkt Perform
2023-09-28 開始されました Raymond James Mkt Perform
2023-09-18 開始されました UBS Buy
2023-07-27 開始されました Scotiabank Sector Perform
2023-07-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-06-14 再開されました Credit Suisse Outperform
2023-03-21 開始されました Bernstein Underperform
2023-02-22 ダウングレード Oppenheimer Outperform → Perform
2023-02-21 開始されました Citigroup Neutral
2023-01-30 開始されました BMO Capital Markets Market Perform
2023-01-18 開始されました Canaccord Genuity Hold
2022-10-31 アップグレード Oppenheimer Perform → Outperform
2022-07-13 開始されました Cantor Fitzgerald Overweight
2022-06-13 再開されました Wedbush Neutral
2022-04-25 アップグレード Morgan Stanley Equal-Weight → Overweight
2021-11-22 アップグレード William Blair Mkt Perform → Outperform
2021-10-07 再開されました Jefferies Buy
2021-09-09 アップグレード Stifel Hold → Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-04-26 再開されました Credit Suisse Outperform
2021-03-04 再開されました Guggenheim Buy
2021-03-01 アップグレード Evercore ISI In-line → Outperform
2020-08-20 ダウングレード Citigroup Buy → Neutral
2020-08-20 ダウングレード William Blair Outperform → Mkt Perform
2020-08-19 ダウングレード Evercore ISI Outperform → In-line
2020-08-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-08-19 ダウングレード Stifel Buy → Hold
2020-07-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-07-06 繰り返されました Citigroup Buy
2020-01-28 開始されました BMO Capital Markets Market Perform
2020-01-27 開始されました BMO Capital Markets Market Perform
2020-01-24 アップグレード RBC Capital Mkts Sector Perform → Outperform
2019-11-27 アップグレード Barclays Equal Weight → Overweight
2019-11-12 開始されました SunTrust Buy
2019-10-17 再開されました BofA/Merrill Buy
2019-05-23 再開されました Citigroup Buy
2019-04-09 再開されました Raymond James Outperform
2019-01-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-12-14 開始されました Wolfe Research Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-07 繰り返されました Stifel Buy
2018-08-03 繰り返されました Stifel Buy
すべてを表示

Biomarin Pharmaceutical Inc (BMRN) 最新ニュース

pulisher
04:24 AM

Proficio Capital Partners LLC Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

04:24 AM
pulisher
Mar 07, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Mar 07, 2025
pulisher
Mar 07, 2025

BioMarin Pharmaceutical Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

BioMarin at TD Cowen Conference: Strategic Growth and Innovation - Investing.com

Mar 06, 2025
pulisher
Mar 05, 2025

First Week of October 17th Options Trading For BioMarin Pharmaceutical (BMRN) - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Phenylketonuria Treatment Market Projected To Witness Substantial Growth, 2025-2032: BioMarin Pharmaceutical - EIN News

Mar 05, 2025
pulisher
Mar 05, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

The Strong Earnings Posted By BioMarin Pharmaceutical (NASDAQ:BMRN) Are A Good Indication Of The Strength Of The Business - Simply Wall St

Mar 04, 2025
pulisher
Mar 04, 2025

Statutory Profit Doesn't Reflect How Good BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings Are - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Sanctuary Advisors LLC - Defense World

Mar 04, 2025
pulisher
Mar 01, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position Lessened by Handelsbanken Fonder AB - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Los Angeles Capital Management LLC Purchases 28,431 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

BMRN or CSLLY: Which Is the Better Value Stock Right Now? - Yahoo Finance

Feb 28, 2025
pulisher
Feb 28, 2025

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance Australia

Feb 28, 2025
pulisher
Feb 28, 2025

New York State Common Retirement Fund Has $6.16 Million Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Cantor Fitzgerald Has Positive View of BMRN FY2025 Earnings - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Oppenheimer Upgrades BioMarin Pharmaceutical (NASDAQ:BMRN) to "Outperform" - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Investor Network: BioMarin Pharmaceutical Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Q2 Earnings Estimate for BMRN Issued By Leerink Partnrs - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Research Analysts Set Expectations for BMRN Q1 Earnings - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Global Retirement Partners LLC Increases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CAO Erin Burkhart Sells 1,344 Shares - MarketBeat

Feb 26, 2025
pulisher
Feb 26, 2025

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance

Feb 26, 2025
pulisher
Feb 26, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Principal Financial Group Inc. - MarketBeat

Feb 26, 2025
pulisher
Feb 26, 2025

Principal Securities Inc. Purchases 339 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World

Feb 26, 2025
pulisher
Feb 25, 2025

BioMarin's chief accounting officer sells $91,902 in stock - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

BioMarin Pharmaceutical Officer Sells Shares - TradingView

Feb 25, 2025
pulisher
Feb 25, 2025

Will BioMarin Reveal New Strategic Plans at Upcoming TD Cowen Healthcare Conference? - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Oppenheimer Upgrades BioMarin Pharmaceutical (WBAG:BMRN) - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

Oppenheimer Upgrades BioMarin Pharmaceutical (LSE:0HNC) - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

BioMarin's SWOT analysis: rare disease leader's stock faces growth and competition challenges - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

Oppenheimer Upgrades BioMarin Pharmaceutical (BMRN) - MSN

Feb 25, 2025
pulisher
Feb 25, 2025

BioMarin Expands Board with New Independent Director - MSN

Feb 25, 2025
pulisher
Feb 24, 2025

BioMarin stock rating upgraded to Outperform by Oppenheimer - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

BioMarin expands board, appoints new director By Investing.com - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 24, 2025

BioMarin adds former Horizon CEO to Board of Directors By Investing.com - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 24, 2025

BioMarin expands board, appoints new director - Investing.com India

Feb 24, 2025
pulisher
Feb 24, 2025

BioMarin adds former Horizon CEO to Board of Directors - Investing.com India

Feb 24, 2025
pulisher
Feb 24, 2025

BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors - PR Newswire

Feb 24, 2025
pulisher
Feb 24, 2025

GILD: 3 Pharmaceutical Stocks With Blockbuster Drug Potential - StockNews.com

Feb 24, 2025
pulisher
Feb 24, 2025

3 Pharmaceutical Stocks With Blockbuster Drug Potential - TradingView

Feb 24, 2025
pulisher
Feb 24, 2025

BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView

Feb 24, 2025
pulisher
Feb 24, 2025

Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect? - Yahoo Finance

Feb 24, 2025
pulisher
Feb 24, 2025

BioMarin stock rating upgraded to Outperform by Oppenheimer By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Oppenheimer Upgrades BioMarin Pharmaceutical to Outperform From Market Perform, Price Target is $98 - Marketscreener.com

Feb 24, 2025
pulisher
Feb 23, 2025

BioMarin Pharmaceutical (NASDAQ:BMRN) Releases FY 2025 Earnings Guidance - MarketBeat

Feb 23, 2025
pulisher
Feb 22, 2025

Rhumbline Advisers Purchases 11,025 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat

Feb 22, 2025
pulisher
Feb 22, 2025

BioMarin’s Record Growth and 2025 Outlook - TipRanks

Feb 22, 2025
pulisher
Feb 21, 2025

BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Up on Strong Earnings - MarketBeat

Feb 21, 2025

Biomarin Pharmaceutical Inc (BMRN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$315.91
price up icon 2.67%
$33.01
price down icon 0.81%
$24.14
price up icon 1.81%
$108.78
price down icon 1.85%
biotechnology ONC
$247.07
price down icon 3.85%
大文字化:     |  ボリューム (24 時間):